Commentary|Videos|March 10, 2022

What Pharmacists Should Understand When Assessing, Treating Patients With Ovarian Cancer With Rucaparib

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses what oncology pharmacists should understand about rucaparib when treating ovarian cancer.

Pharmacy Times interviewed Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, on what rucaparib is used to treat and how its mechanism of action works to fight cancer.

During the interview, Morris addressed what oncology pharmacists should understand when assessing and treating patients with ovarian cancer with rucaparib.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!

Latest CME

On-Demand Webinar

Implementing Updated RSV Vaccination Recommendations for Older Adults: Considerations for the Pharmacist (Pharmacy Technician Credit)

0.5 Credit / Immunology

What Pharmacists Should Understand When Assessing, Treating Patients With Ovarian Cancer With Rucaparib

Newsletter

Related Content

Q&A: Making Plant-Based Eating Practical in Pharmacy-Led Cardiometabolic Care

Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment

Strengthening Neurology Care Through Clinical Pharmacy Integration and Collaborative Practice

TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs

Q&A: How Pharmacists Can Address Structural Barriers in Obesity Care

Latest CME

Implementing Updated RSV Vaccination Recommendations for Older Adults: Considerations for the Pharmacist (Pharmacy Technician Credit)

Implementing Updated RSV Vaccination Recommendations for Older Adults: Incorporating ACIP Guidelines (Part 2)

Navigating Diabetes: A Guide to Effective Oral Treatments

Exploring HIV Long-Acting Injectable Uptake: How Pharmacists Can Encourage Long-Acting Injectables to Stem the Spread of HIV

APhA 2026

Optimizing LDL-C Lowering and Adherence to Hyperlipidemia Guidelines

Best Practices for Management of Hyperlipidemia: A Focus on Guidelines and Patient Adherence

Understanding the Pearls and Pitfalls of Nimodipine in Aneurysmal Subarachnoid Hemorrhage: Opportunities to Improve Patient Outcomes

Implementing Updated RSV Vaccination Recommendations for Older Adults: RSV Case Discussion

Implementing Updated RSV Vaccination Recommendations for Older Adults: Incorporating ACIP Guidelines (Pharmacy Technician Credit)

Implementing Updated RSV Vaccination Recommendations for Older Adults: Introduction and Disease Burden (Part 1)

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Empowering Patients With COPD: The Pharmacist's Role in Personalized Treatment Strategies

2025 SABCS Abstracts to Action: From Data to Decisions in HR+ Breast Cancer Care

Implementing Updated RSV Vaccination Recommendations for Older Adults: RSV Case Discussion (Pharmacy Technician Credit)

Advancing AML Care: Equipping Pharmacists to Implement Menin Inhibitor Therapies with Precision

Advancing Acute Pain Care: Breakthrough Non-Opioid Therapies and the Pharmacist's Critical Role

Hyperlipidemia Overview and the Clinical and Economic Burden

The Role of the Pharmacist in the Management of Hyperlipidemia

Improving Patient Outcomes in Seasonal and Perennial Allergic Conjunctivitis

Improving Patient Outcomes in Seasonal and Perennial Allergic Conjunctivitis (Pharmacy Technician Credit)

Implementing Updated RSV Vaccination Recommendations for Older Adults: Introduction and Disease Burden (Pharmacy Technician Credit)

Implementing Updated RSV Vaccination Recommendations for Older Adults: Considerations for the Pharmacist (Part 3)

Trending on Pharmacy Times

Nipah Outbreak in India Poses Low Global Risk Despite Lack of Approved Treatments

TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs

Q&A: Making Plant-Based Eating Practical in Pharmacy-Led Cardiometabolic Care

Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment

SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury